CVS Health (CVS.N) has announced that it will discontinue Johnson & Johnson's (JNJ.N)'s psoriasis drug Stelara from its main formularies from July 1. The company's pharmacy benefit management unit, Caremark, will transition to biosimilar versions of Stleara, such as Sandoz's (SDZ.S) Pyzchiva and Biocon Biologics' (BIOC.NS) Yesintek. Most members of Caremark will pay $0 out-of-pocket for their therapy. The move is seen as a significant savings for clients and supports broader access to proven therapies.